MAP2K7 and neoplasm: In high-grade serous ovarian cancer cells, co-treatment of Saracatinib (SFKs inhibitor, AZD0530) and selumetinib (MEK inhibitor, AZD6244) reduced SFE and ALDH1 positive cells and, in vivo the loss of tumor-initiating cells following serial tumor xenografting [50].